HAVCR2 and hepatocellular carcinoma: Cobolimab, an anti-TIM3 mAb, in combination with dostarlimab, an anti-PD-1 mAb, led to an ORR of 46% among 16 evaluable patients with untreated HCC in an ongoing phase 2 study [87] (Table 2).